|
December 2001 (v01-n02) |
|
- Main Story - pgs. 1-24 Targeted Genetics (TGEN)
- Macro Market Commentary - pg. 25
- News Briefs - pgs. 26-27
- NIBM Model Portfolio & Updates - pgs. 27-28
|
 |
|
| This month's Main Story is on the gene therapy
company Targeted Genetics. This company is a leader in the field with tgAAVCF, their cure
for Cystic Fibrosis, leading their pipeline in a Phase II study. The company is also
evaluating two lipid vector carriers of an engineered E1A gene for head and neck and
ovarian cancer. They have a number of preclinical candidates, including a gene therapy
drug targeting the same gene as the Immunex/Amgen rheumatoid arthritis drug Enbrel. |
 |
|
| The following is an outline of this issue of
the NIBM Newsletter. |
Subscriber direct access |
|
| |
|
|
- Main Story
- Summary
- Table - Financials at a Glance
- Investment Case
- Disclosure
- Gene Therapy Defined
- Gene Therapy Basics
- The Vector
- Sidebar: "Four things that vectors must do"
- Table: Vector Comparison Table
- Vector Shopping List
- Adenovirus
- Retrovirus
- Sidebar: "In vivo vs. in vitro"
- Adeno-associated Virus
- Herpes Simplex Virus
- HIV
- Naked DNA
- Vector Analysis
- Sidebar: "Jesse Gelsinger"
- Targeted's Products
- tgAAVCF
- Table: TGEN Product Pipeline
- Sidebar: "If tgAAVCF needs a new delivery method, we have
some insight"
- tgDCCE1A
- tgLPDE1A
- tgAAVFVIII
- tgAAV-TNFR:Fc
- tgAAC09
- tgAAV-VLDLr
- tgAAV-AGA
- Glioma (Ad)
- Engelhardt Technology
- Partnerships
- Table: Partners
- American Home Products (AHP)
- Biogen (BGEN)
- Genzyme (GENZ)
- IAVI/CRI
- CellTech (CLL)
- Elan/Emerald Gene Systems
- Sangamo (SGMO) & Aventis (NYSE-ADR:AVE)
- CellExSys
- Production/Operations
- Financial Situation
Regulatory & Business Environment Challenges
- RAC
- Dr. Mike Sand's Cancerous Rats
-
Competitors
- Table: Competitors
-
- Macro-level view of gene therapy -- Beyond curing mice
- Back to Targeted Genetics
-
- Milestones
-
- Table: Milestones
- What Can Go Wrong
- Macro Market Commentary
- News Briefs
- Amgen pays $16B for Immunex
- NASDAQ-100 moves towards biotechnology
- Introgen soars on good news
- NIBM Model Portfolio and Updates
- Updates on each Model Portfolio member
|
|
|
| |
|
|
 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
